Xiamen Amoytop Biotech Co., Ltd. (SHA: 688278)
China
· Delayed Price · Currency is CNY 73.72
-0.60 (-0.81%)
Nov 21, 2024, 11:29 AM CST
Xiamen Amoytop Biotech Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2016 |
| Net Income | 740.69 | 555.45 | 287.02 | 181.2 | 116.57 | 64.29 | Upgrade
|
| Depreciation & Amortization | 57.56 | 57.56 | 48.07 | 43.15 | 38.17 | 37.78 | Upgrade
|
| Other Amortization | 10.66 | 10.66 | 2.3 | 1.18 | 0.64 | 0.15 | Upgrade
|
| Loss (Gain) From Sale of Assets | 0.87 | 0.87 | -0.03 | 1.8 | 1.13 | 0.01 | Upgrade
|
| Asset Writedown & Restructuring Costs | 12.76 | 12.76 | - | - | - | - | Upgrade
|
| Loss (Gain) From Sale of Investments | -6.2 | -6.2 | -3.92 | -6.78 | -4.84 | - | Upgrade
|
| Provision & Write-off of Bad Debts | 0.35 | 0.35 | -1.41 | -2.34 | -0.19 | 2.28 | Upgrade
|
| Other Operating Activities | -274.45 | 1.72 | 0.59 | 1.58 | 2.8 | 3.54 | Upgrade
|
| Change in Accounts Receivable | -205.76 | -205.76 | -15.51 | -24.54 | -42.42 | 9.06 | Upgrade
|
| Change in Inventory | -57.29 | -57.29 | -13.24 | -16.87 | -29.02 | -15.32 | Upgrade
|
| Change in Accounts Payable | 153.19 | 153.19 | 61.89 | 63.92 | 9.69 | 19.25 | Upgrade
|
| Operating Cash Flow | 421.16 | 512.1 | 363.16 | 234.78 | 92.61 | 123.3 | Upgrade
|
| Operating Cash Flow Growth | -18.90% | 41.01% | 54.68% | 153.52% | -24.89% | 38.31% | Upgrade
|
| Capital Expenditures | -283.54 | -288.46 | -219.17 | -190.93 | -118.81 | -44.83 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.06 | 0.04 | 0.11 | 0.34 | 0.06 | 0.1 | Upgrade
|
| Investment in Securities | -155.46 | -17.35 | -70.34 | 78.66 | -264.18 | - | Upgrade
|
| Other Investing Activities | - | - | - | 0.09 | 0.94 | - | Upgrade
|
| Investing Cash Flow | -438.95 | -305.76 | -289.4 | -111.84 | -381.99 | -44.73 | Upgrade
|
| Short-Term Debt Issued | - | - | - | 10 | 18.92 | 60 | Upgrade
|
| Total Debt Issued | - | - | - | 10 | 18.92 | 60 | Upgrade
|
| Short-Term Debt Repaid | - | - | -10 | -18.92 | -60 | -70 | Upgrade
|
| Long-Term Debt Repaid | - | -6.26 | -7.69 | -4.61 | - | - | Upgrade
|
| Total Debt Repaid | -6.26 | -6.26 | -17.69 | -23.53 | -60 | -70 | Upgrade
|
| Net Debt Issued (Repaid) | -6.26 | -6.26 | -17.69 | -13.53 | -41.08 | -10 | Upgrade
|
| Issuance of Common Stock | - | - | - | - | 348.16 | - | Upgrade
|
| Common Dividends Paid | -166.79 | -86.65 | -40.68 | -20.68 | -12.72 | -3.39 | Upgrade
|
| Other Financing Activities | -1.08 | - | - | - | -13.24 | -4.47 | Upgrade
|
| Financing Cash Flow | -174.13 | -92.91 | -58.37 | -34.2 | 281.11 | -17.86 | Upgrade
|
| Foreign Exchange Rate Adjustments | -0.02 | -1.11 | 0.03 | -0.49 | -0.96 | 0.12 | Upgrade
|
| Net Cash Flow | -191.94 | 112.32 | 15.42 | 88.25 | -9.23 | 60.82 | Upgrade
|
| Free Cash Flow | 137.62 | 223.64 | 143.99 | 43.85 | -26.2 | 78.48 | Upgrade
|
| Free Cash Flow Growth | -49.93% | 55.31% | 228.34% | - | - | 5.27% | Upgrade
|
| Free Cash Flow Margin | 5.30% | 10.65% | 9.43% | 3.87% | -3.30% | 10.75% | Upgrade
|
| Free Cash Flow Per Share | 0.34 | 0.55 | 0.36 | 0.11 | -0.07 | 0.22 | Upgrade
|
| Cash Income Tax Paid | 216.7 | 168.12 | 112.85 | 71.33 | 63.82 | 42.12 | Upgrade
|
| Levered Free Cash Flow | -78.04 | 41.08 | 127.17 | 11.47 | -64.97 | 79.15 | Upgrade
|
| Unlevered Free Cash Flow | -77.73 | 41.4 | 127.56 | 12.14 | -63.43 | 81.26 | Upgrade
|
| Change in Net Working Capital | 395.01 | 150.78 | -71.31 | -20.21 | 62.72 | -20.07 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.